Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2586)	9/15/2009 6:35:39 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CUR closed near its intraday H and was up 22.31% on volume of 656,976 about 7x its ADV bigcharts.marketwatch.com It announced last Wednesday that it received notice of allowance from the USPTO for its patent entitled “Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions,” number 11/281,640. The CEO said:“The transplantation of our neural stem cells to treat degenerative conditions of the nervous system is at the heart of Neuralstem’s mission.” According to one of its executives,the claims in this patent cover the manufacturing process of CUR's future products from all regions of the human central nervous system (brain and spinal cord) through July of 2026.<g> The patented technology is capable to produce neural stem cells of the human brain and spinal cord in commercial quantities, and able to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company's possible 'treatment targets' include among others: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington’s disease and ALS. (CUR has an IND under review with the FDA for ALS.) Pre-clinical work has shown that it is capable to extend the life of rats with ALS,as reported in the journal TRANSPLANTATION, in October 16, 2006, in collaboration with researchers from Johns Hopkins, and also able to reverse paralysis in rats with Ischemic Spastic Paraplegia,as reported in NEUROSCIENCE in June 29, 2007,those studies were made in collaboration with researchers from the Univ. of CA, SD. Although the stock has a good amount of resistance from its Nov & Dec 2008 Hs at the $2.20 level, it seems that with some good news,the stock could get to $2.70 <g> As mentioned, it closed near its H with good volume and above its Aug 10 H of $1.45 bigcharts.marketwatch.com Bernard